Merck keeps pumping up sotatercept, posting fresh data ahead of FDA approval ruling

Merck keeps pumping up sotatercept, posting fresh data ahead of FDA approval ruling

Source: 
Fierce Biotech
snippet: 

Merck & Co. has unwrapped a fresh set of clinical data on sotatercept, providing further evidence of the safety and efficacy of the cardiovascular drug candidate ahead of a FDA ruling on whether to approve the jewel of the $11.5 billion Acceleron Pharma buyout.